Monitoring of viral load prior to and after T-cell therapy
| Patient no. . | Antiviral chemotherapy prior to T-cell therapy, wk (antiviral drugs) . | Time of T-cell therapy (day after Tx) . | Immunosuppression at T-cell transfer . | Viral load during 4-8 weeks prior to T-cell therapy (mean/peak titer) . | Viral load during 2-5 weeks after T-cell therapy . | Increase in viral load after transfer . |
|---|---|---|---|---|---|---|
| 1 | 10 (GCV/FC) | 108 | CSA/MMF/Pred 0.5 | 101 000/180 000 | 8 600 | Yes† |
| 2 | 10 (FC/GCV) | 120/186 | CSA/Pred 0.5 | 4 000/4 000 | 0 | No |
| 3 | 6 (GCV/FC) | 144 | CSA/Pred 0.3 | 300‡ | 0 | No |
| 4 | 6 (GCV/FC) | 79 | CSA | 11 800/46 000 | 0 | No |
| 5 | 10 (GCV/FC) | 120/180 | CSA/Pred 0.2 | 117 800/200 000 | 1 000/02-153 | No |
| 6 | 8 (GCV/FC) | 108 | — | 1 700/12 000 | 0 | No |
| 7 | 8 (GCV/CDV) | 479 | FK506/Pred 0.3 | 300‡/100‡/02-155 | 0 | No |
| 8 | 4 (GCV/FC) | 135 | CSA/Pred 1 | 400/800 | 0 | Yes2-154 |
| Patient no. . | Antiviral chemotherapy prior to T-cell therapy, wk (antiviral drugs) . | Time of T-cell therapy (day after Tx) . | Immunosuppression at T-cell transfer . | Viral load during 4-8 weeks prior to T-cell therapy (mean/peak titer) . | Viral load during 2-5 weeks after T-cell therapy . | Increase in viral load after transfer . |
|---|---|---|---|---|---|---|
| 1 | 10 (GCV/FC) | 108 | CSA/MMF/Pred 0.5 | 101 000/180 000 | 8 600 | Yes† |
| 2 | 10 (FC/GCV) | 120/186 | CSA/Pred 0.5 | 4 000/4 000 | 0 | No |
| 3 | 6 (GCV/FC) | 144 | CSA/Pred 0.3 | 300‡ | 0 | No |
| 4 | 6 (GCV/FC) | 79 | CSA | 11 800/46 000 | 0 | No |
| 5 | 10 (GCV/FC) | 120/180 | CSA/Pred 0.2 | 117 800/200 000 | 1 000/02-153 | No |
| 6 | 8 (GCV/FC) | 108 | — | 1 700/12 000 | 0 | No |
| 7 | 8 (GCV/CDV) | 479 | FK506/Pred 0.3 | 300‡/100‡/02-155 | 0 | No |
| 8 | 4 (GCV/FC) | 135 | CSA/Pred 1 | 400/800 | 0 | Yes2-154 |
Antiviral chemotherapy was stopped in all 8 patients prior to the transfusion of CMV-specific T-cell lines. Viral load is presented as CMV-DNA copies/mL blood.
GCV indicates ganciclovir; FC, foscarnet; CSA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; CDV, cidofovir.
Patient refused further antiviral therapy (second infusion of T cells, antiviral chemotherapy).
Only tested semiquantitatively.
Clearance after second T-cell transfer.
Patient with a previous history of CMV interstitial pneumonitis was PCR-negative on the day of T-cell infusion (but still tested positive by antigenemia assay).
Increase in viral load following steroid treatment for relapse of the underlying hematologic malignancy.